[1]张少晗,应燕萍,赵慧函,等.1990-2019年我国多发性骨髓瘤疾病负担及其变化趋势分析[J].医学信息,2022,35(22):23-27.[doi:10.3969/j.issn.1006-1959.2022.22.004]
　ZHANG Shao-han,YING Yan-ping,ZHAO Hui-han,et al.Analysis of the Burden of Multiple Myeloma and its Changing Trend in China from 1990 to 2019[J].Journal of Medical Information,2022,35(22):23-27.[doi:10.3969/j.issn.1006-1959.2022.22.004]
点击复制

1990-2019年我国多发性骨髓瘤疾病负担及其变化趋势分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年22期
页码:
23-27
栏目:
卫生管理信息学
出版日期:
2022-11-15

文章信息/Info

Title:
Analysis of the Burden of Multiple Myeloma and its Changing Trend in China from 1990 to 2019
文章编号:
1006-1959（2022）22-0023-05
作者:
张少晗; 应燕萍; 赵慧函; 等
（广西医科大学第一附属医院护理部1，副院长办公室2，血液内科3，检验科4，广西 南宁 530021）
Author(s):
ZHANG Shao-han; YING Yan-ping; ZHAO Hui-han; et al.
(Department of Nursing1,Vice President’s Office2,Department of Hematology3,Department of Laboratory4,the First Affiliated Hospital of Guangxi Medical University,Nanning 530021,Guangxi,China)
关键词:
多发性骨髓瘤; 疾病负担; Joinpoint回归分析; 伤残调整寿命年
Keywords:
Multiple myeloma; Disease burden; Joinpoint regression analysis; Disability-adjusted life years
分类号:
R181.2；R733.3
DOI:
10.3969/j.issn.1006-1959.2022.22.004
文献标志码:
A
摘要:
目的 分析1990-2019年我国多发性骨髓瘤（MM）的疾病负担及变化趋势，旨在为多发性骨髓瘤疾病的防控提供科学、有效的依据。方法 提取2019年全球疾病负担数据库（GBD2019）中的我国部分数据及全球数据，采用发病率、死亡率、伤残损失健康寿命年（YLDs）、早死损失寿命年（YLLs）、伤残调整寿命年（DALYs）进行描述，利用Joinpoint回归模型分析多发性骨髓瘤的标化发病率、标化死亡率、标化YLDs率、标化YLLs率和标化DALYs率的平均年度百分比变化率（AAPC），以及多发性骨髓瘤的疾病负担、变化趋势。结果 2019年，我国多发性骨髓瘤病例数为18 793例，发病率为1.32/10万；死亡病例13 422例，死亡率为0.94/10万；DALYs为347 453例，DALYs率为24.43/10万；与1990年相比，2019年多发性骨髓瘤的发病率、死亡率及DALYs率变化率为2.38%、0.92%及0.95%。男性的发病率、死亡率、DALYs率均高于女性，且随年龄增长均呈上升趋势；1990-2019年，我国多发性骨髓瘤标化发病率（AAPC=1.00，P＜0.05）、标化死亡率（AAPC=0.16，P＜0.05）和标化DALYs率（AAPC=0.21，P＜0.05）均呈上升趋势。结论 1990-2019年，我国多发性骨髓瘤疾病负担趋势升高，涨幅高于全球数据水平。
Abstract:
Objective To analyze the disease burden and change trend of multiple myeloma (MM) in China from 1990 to 2019, so as to provide scientific and effective basis for the prevention and control of multiple myeloma.Methods China ’s data and global data in the Global Burden of Disease Database 2019 (GBD2019) were extracted. Morbidity, mortality, years of life lost due to disability (YLDs), years of life lost due to premature death (YLLs), and disability adjusted life years (DALYs) were used for description. The Joinpoint regression model was used to analyze the average annual percentage change rate (AAPC) of the standardized incidence rate, standardized mortality rate, standardized YLDs rate, standardized YLLs rate and standardized DALYs rate of multiple myeloma, as well as the disease burden and changing trend of multiple myeloma.Results In 2019, there were 18 793 cases of multiple myeloma in China, with an incidence of 1.32/100 000. There were 13 422 deaths, with a mortality rate of 0.94/100 000. The number of DALYs was 347 453, and the DALYs rate was 24.43/100 000. Compared with 1990, the incidence, mortality and DALYs rate of multiple myeloma in 2019 were 2.38%, 0.92% and 0.95%, respectively. The morbidity, mortality and DALYs rate of male were higher than those of female, and increased with age. From 1990 to 2019, the standardized incidence rate (AAPC=1.00, P<0.05), standardized mortality rate (AAPC=0.16, P<0.05) and standardized DALYs rate (AAPC=0.21, P<0.05) of multiple myeloma in China showed an upward trend.Conclusion From 1990 to 2019, the disease burden of multiple myeloma in China has increased, and the differences between different genders and ages are statistically significant, the increase rate is higher than the global data level.

参考文献/References:

[1]Rajkumar SV.Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management[J].Am J Hematol,2018,93(8):981-1114.[2]Durie BGM,Hoering A,Abidi MH,et al.Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial[J].Lancet,2017,389(10068):519-527.[3]刘莹,隋靖喆,朱丽华,等.IL-6通过STAT3/Notch信号通路调控多发性骨髓瘤耐药细胞株对硼替佐米的化疗敏感性[J].中国实验血液学杂志,2022,30(5):1474-1481.[4]Iorio R.The Future Is Here: Bundled Payments and International Statistical Classification of Diseases, 10th Revision[J].J Arthroplasty,2016,31(5):931. [5]GBD 2019 Diseases and Injuries Collaborators.Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019[J].Lancet,2020,396(10258):1204-1222. [6]古建昌,宋继武,刘云,等.1990-2019年我国口腔癌疾病负担及其变化趋势分析[J].中国预防医学杂志,2022,23(6):457-461.[7]李辉章,杜灵彬.Joinpoint回归模型在肿瘤流行病学时间趋势分析中的应用[J].中华预防医学杂志,2020,54(8):908-912.[8]聂艳武,马玉花,王琛琛,等.基于Joinpoint和APC模型的2010-2019年新疆克拉玛依市队列人群HPV感染特征及趋势分析[J].现代预防医学,2022,49(11):1921-1925.[9]陈慧玲,马成成,柴晔,等.基于硼替佐米治疗反应及BTK表达水平建立非初治多发性骨髓瘤临床预测模型[J].中国实验血液学杂志,2022,30(4):1139-1143. [10]王超雨,唐倩,孙士县,等.侵袭性B细胞非霍奇金淋巴瘤、惰性B细胞非霍奇金淋巴瘤和多发性骨髓瘤患者乙型肝炎病毒感染情况分析[J].白血病·淋巴瘤,2019,28(6):327-332.[11]Thokerunga E,Ntege C,Ahmed AO.Are African primary physicians suspicious enough? Challenges of multiple myeloma diagnosis in Africa[J].Egypt J Intern Med,2021. [12]Guzdar A,Costello C.Supportive Care in Multiple Myeloma[J].Curr Hematol Malig Rep,2020,15(2):56-61. [13]任荣,热孜万古丽·阿布都拉,姜鸿.多发性骨髓瘤误诊为亚急性肾间质肾炎一例报道并文献复习[J].中国全科医学,2017,20(14):1783-1786. [14]孙真真,许德英,王小利,等.外周血中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值对初诊多发性骨髓瘤患者总生存情况的预测价值[J].中国慢性病预防与控制,2020,28(3):213-217.[15]Blimark C,Holmberg E,Mellqvist UH,et al.Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients[J].Haematologica,2015,100(1):107-113. [16]Liu J,Liu W,Mi L,et al.Incidence and mortality of multiple myeloma in China, 2006-2016: an analysis of the Global Burden of Disease Study 2016[J].J Hematol Oncol,2019,12(1):136. [17]Derman BA,Langerman SS,Maric M,et al.Sex differences in outcomes in multiple myeloma[J].Br J Haematol,2021,192(3):e66-e69. [18]J?覿ger U,Fridrik M,Zeitlinger M,et al.Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response[J].Haematologica,2012,97(9):1431-1438. [19]Muthu Raja KR,Rihova L,Zahradova L,et al.Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma[J].PLoS One,2012,7(10):e47077. [20]Marinac CR,Birmann BM,Lee IM,et al.Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts[J].Br J Cancer,2018,118(7):1013-1019. [21]Sergentanis TN,Zagouri F,Tsilimidos G,et al.Risk Factors for Multiple Myeloma: A Systematic Review of Meta-Analyses[J].Clin Lymphoma Myeloma Leuk,2015,15(10):563-577. [22]王玥,孟楠.基于Joinpoint回归分析我国成人超重、肥胖流行趋势的性别差异[J].中国卫生统计,2021,38(4):546-548.[23]李瑶玥,王桂新.社会经济因素对中国居民肥胖的影响[J].人口与发展,2022,28(5):107-125.[24] Kazandjian D.Multiple myeloma epidemiology and survival: A unique malignancy[J].Semin Oncol,2016,43(6):676-681. [25]张新芸,华冰清,高山,等.多发性骨髓瘤化疗医院感染风险预测模型的建立及应用价值[J].中华医院感染学杂志,2021,31(9):1396-1400. [26]Salvini M,D’Agostino M,Bonello F,et al.Determining treatment intensity in elderly patients with multiple myeloma[J].Expert Rev Anticancer Ther,2018,18(9):917-930. [27]Cowan AJ,Allen C,Barac A,et al.Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016[J].JAMA Oncol,2018,4(9):1221-1227.[28]项鑫,王乙.中国人口老龄化现状、特点、原因及对策[J].中国老年学杂志,2021,41(18):4149-4152.

相似文献/References:

[1]贾海英,黄睿,王玲玲,等.多发性骨髓瘤患者淋巴细胞亚群变化对免疫功能的影响研究[J].医学信息,2018,31(01):147.[doi:10.3969/j.issn.1006-1959.2018.01.057]
　JIA Hai-ying,HUANG Rui,WANG Ling-ling,et al.The Effect of Lymphocyte Subgroup Changes on Immune Function in Patients with Multiple Myeloma[J].Journal of Medical Information,2018,31(22):147.[doi:10.3969/j.issn.1006-1959.2018.01.057]
[2]黄珍艳.实验室指标对多发性骨髓瘤的诊断价值分析[J].医学信息,2018,31(05):155.[doi:10.3969/j.issn.1006-1959.2018.05.056]
　HUANG Zhen-yan.Diagnostic Value of Laboratory Markers for Multiple Myeloma[J].Journal of Medical Information,2018,31(22):155.[doi:10.3969/j.issn.1006-1959.2018.05.056]
[3]冯江芳.多发性骨髓瘤患者校正血钙的临床分析[J].医学信息,2018,31(10):87.[doi:10.3969/j.issn.1006-1959.2018.10.026]
　FENG Jiang-fang.Clinical Analysis of Corrected Serum Calcium in Patients with Multiple Myeloma[J].Journal of Medical Information,2018,31(22):87.[doi:10.3969/j.issn.1006-1959.2018.10.026]
[4]王晓雪,王芝涛,秦 慧.血小板与淋巴细胞比值在多发性骨髓瘤预后中的价值[J].医学信息,2022,35(12):109.[doi:10.3969/j.issn.1006-1959.2022.12.026]
　WANG Xiao-xue,WANG Zhi-tao,QIN Hui.Prognostic Value of Platelet to Lymphocyte Ratio in Multiple Myeloma[J].Journal of Medical Information,2022,35(22):109.[doi:10.3969/j.issn.1006-1959.2022.12.026]
[5]王 然,孙言非.血清免疫固定电泳、血清蛋白电泳及免疫球蛋白定量对 多发性骨髓瘤的临床诊断价值[J].医学信息,2019,32(11):173.[doi:10.3969/j.issn.1006-1959.2019.11.054]
　WANG Ran,SUN Yan-fei.Clinical Diagnostic Value of Serum Immunofixation Electrophoresis,Serum Protein Electrophoresis and Immunoglobulin Quantification for Multiple Myeloma[J].Journal of Medical Information,2019,32(22):173.[doi:10.3969/j.issn.1006-1959.2019.11.054]
[6]金 英.硼替佐米治疗老年多发性骨髓瘤的效果[J].医学信息,2020,33(06):146.[doi:10.3969/j.issn.1006-1959.2020.06.047]
　JIN Ying.Effect of Bortezomib in the Treatment of Elderly Multiple Myeloma[J].Journal of Medical Information,2020,33(22):146.[doi:10.3969/j.issn.1006-1959.2020.06.047]
[7]燕法红,邱志远,李乾鹏,等.激活蛋白-1家族JunB、c-Jun、c-Maf、c-Fos在多发性骨髓瘤中的表达[J].医学信息,2021,34(23):44.[doi:10.3969/j.issn.1006-1959.2021.23.012]
　YAN Fa-hong,QIU Zhi-yuan,LI Qian-peng,et al.Expression of Activator Protein-1 Family JunB,c-Jun,c-Maf,c-Fos in Multiple Myeloma[J].Journal of Medical Information,2021,34(22):44.[doi:10.3969/j.issn.1006-1959.2021.23.012]
[8]刘文玲,朱明明,马德花.miR-125b在多发性骨髓瘤中的表达及与预后的关系[J].医学信息,2023,36(21):61.[doi:10.3969/j.issn.1006-1959.2023.21.013]
　LIU Wen-ling,ZHU Ming-ming,MA De-hua.Expression of miR-125b in Multiple Myeloma and its Relationship with Prognosis[J].Journal of Medical Information,2023,36(22):61.[doi:10.3969/j.issn.1006-1959.2023.21.013]
[9]覃泽东,夏玉梅,陈 莉,等.多发性骨髓瘤合并颅内浆细胞瘤的临床及影像学特点分析[J].医学信息,2021,34(05):111.[doi:10.3969/j.issn.1006-1959.2021.05.031]
　QIN Ze-dong,XIA Yu-mei,CHEN Li,et al.Analysis of Clinical and Imaging Characteristics of Multiple Myeloma Combined with Intracranial Plasmacytoma[J].Journal of Medical Information,2021,34(22):111.[doi:10.3969/j.issn.1006-1959.2021.05.031]
[10]晏建国,罗 萍,胡 飞,等.多发性骨髓瘤患者EB病毒检测及其临床意义[J].医学信息,2021,34(15):86.[doi:10.3969/j.issn.1006-1959.2021.15.022]
　YAN Jian-guo,LUO Ping,HU Fei,et al.Detection of Epstein-Barr Virus in Patients with Multiple Myeloma and Its Clinical Significance[J].Journal of Medical Information,2021,34(22):86.[doi:10.3969/j.issn.1006-1959.2021.15.022]

更新日期/Last Update: 1900-01-01